环磷酰胺治疗脑瘫或神经肌肉疾病患儿骨质疏松症的临床研究。 （注：原文中药物名称有误，正确的是帕米膦酸二钠“pamidronate”，这里按照正确的名称翻译为帕米膦酸二钠环磷酰胺表述有误，推测可能是想表达帕米膦酸二钠，以下是纠正后的译文） 帕米膦酸二钠循环给药治疗脑瘫或神经肌肉疾病患儿骨质疏松症的临床研究。
Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study.
作者信息
Allington Nanni, Vivegnis Danielle, Gerard Paul
机构信息
Department of Orthopaedic Surgery, CHR La Citadelle, Liège, Belgium.
出版信息
Acta Orthop Belg. 2005 Feb;71(1):91-7.
Eighteen osteoporotic (Z-score at or below 2.5) nonambulatory children with cerebral palsy or a neuromuscular disorder received cyclic intravenous administration of pamidronate. One year after treatment, bone densitometry showed an improvement in all patients: a mean increase of 13% +/- 15% standard deviation (SD) (p < 10(-5)) on the global data, and a mean increase of 27% +/- 15% (p < 10(-5)) on the most significant area for each individual patient. Clinical improvement was found in all patients, with a decrease in pain on manipulation, and no new fractures. No major adverse effects were reported. Cyclic intravenous administration of pamidronate is a useful tool in the treatment of osteoporosis in these children.
18名患有脑瘫或神经肌肉疾病的骨质疏松症（Z值等于或低于2.5）的非行走儿童接受了帕米膦酸的周期性静脉给药。治疗一年后，骨密度测量显示所有患者均有改善：整体数据平均增加13%±15%标准差（SD）（p<10⁻⁵），每位患者最显著区域平均增加27%±15%（p<10⁻⁵）。所有患者均有临床改善，手法操作时疼痛减轻，且无新骨折发生。未报告重大不良反应。帕米膦酸的周期性静脉给药是治疗这些儿童骨质疏松症的有效手段。
Zotero 插件